Suhaichuan Biotechnology

Jiangsu Suhaichuan Biotechnology is a clinical-stage biopharmaceutical company based in Taizhou, China, specializing in the development of next-generation peptide therapeutics for metabolic diseases. Founded by Dr. Su Haichuan, a former senior scientist at Eli Lilly with extensive experience in incretin research, the company focuses on multi-receptor agonists targeting GLP-1, GIP, and Glucagon receptors. Its lead program, SHC014, is a dual GLP-1/GIP receptor agonist currently in Phase 1 clinical trials for the treatment of obesity and type 2 diabetes. The company's pipeline also includes SHC015, a triple agonist aimed at treating nonalcoholic steatohepatitis (NASH) and severe obesity. Suhaichuan leverages a proprietary peptide optimization platform to enhance the pharmacological properties of its candidates, aiming for improved potency and longer half-lives. The company is backed by prominent venture capital firms including HighLight Capital and Oriza Holdings.